SenesTech (NASDAQ:SNES) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of SenesTech (NASDAQ:SNES) in a research report released on Thursday morning. The firm issued a sell rating on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $3.50 price target on shares of SenesTech in a research report on Tuesday, May 14th.

SenesTech Price Performance

NASDAQ SNES opened at $0.50 on Thursday. The firm’s 50 day moving average price is $0.69 and its two-hundred day moving average price is $0.83. The company has a current ratio of 6.91, a quick ratio of 5.69 and a debt-to-equity ratio of 0.03. SenesTech has a twelve month low of $0.50 and a twelve month high of $14.04.

SenesTech (NASDAQ:SNES) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). SenesTech had a negative return on equity of 181.46% and a negative net margin of 545.82%. The company had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $0.43 million. During the same period last year, the company earned ($15.85) earnings per share. As a group, sell-side analysts forecast that SenesTech will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On SenesTech

An institutional investor recently bought a new position in SenesTech stock. McAdam LLC bought a new stake in SenesTech, Inc. (NASDAQ:SNES) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 64,348 shares of the company’s stock, valued at approximately $44,000. McAdam LLC owned approximately 1.25% of SenesTech as of its most recent filing with the SEC. 5.19% of the stock is currently owned by institutional investors and hedge funds.

About SenesTech

SenesTech, Inc develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.